Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
Recruiting · NCT05498675 · Observational (researchers observe without assigning treatment) · Lead sponsor: Beijing Friendship Hospital
View the official record on ClinicalTrials.gov →Interventions studied
ACEI/ARBSacubitril / Valsartan Oral Tablet [Entresto]
What this trial is about
The purpose of this study is to investigate the effect of sacubitril/valsartan on cardiac function assessed by cardiac magnetic resonance (CMR) in hypertensive patients stratified by BMI.
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with essential hypertension
- 18-70 years old
- No major barriers to provide written consent
Exclusion criteria
- Secondary hypertension, except because of sleep apnea
- cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months
- Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases)
- Unable to understand or comply with the study procedures
Where it is running
1 location listed.
- Beijing Friendship Hospital, Capital Medical University - Beijing, Beijing Municipality, China